All Patients With TNBC Should Receive Immune Checkpoint Inhibitor Therapy: Yes vs No

Faculty will critically evaluate current evidence, including trial data, biomarkers, and patient selection considerations, to clarify where immunotherapy offers meaningful benefit and where uncertainty remains in the treatment of triple-negative breast cancer. Presenters will provide expert insight into translating evolving data into real-world clinical decision-making. Through this balanced discussion, participants will gain a nuanced understanding of the risks, benefits, and limitations of universal versus selective use of immune checkpoint inhibitors in TNBC.